J&J Reveling In RAVEL Drug-Coated Stent Data: No Restenosis At Six Months
Johnson and Johnson/Cordis' European RAVEL study data sets a high standard for other drug-coated stent developers, including no restenosis at six-month follow-up.
Johnson and Johnson/Cordis' European RAVEL study data sets a high standard for other drug-coated stent developers, including no restenosis at six-month follow-up.